

Real-life experience in switching to new extended half-life products at European haemophilia centres.

Peyvandi F^{1,2}, Garagiola I¹, Boscarino M¹, Ryan A³, Hermans C⁴, Makris M^{5,6}.

Author information

- 1 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Fo Luigi Villa, Milan, Italy.
- 2 Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
- 3 European Association for Hemophilia and Allied Disorders, Brussels, Belgium.
- 4 Division of Haematology, Haemostasis and Thrombosis Unit, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Belgium.
- 5 Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK.
- 6 Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK.

Abstract

The concept of replacement therapy in haemophilia is changing significantly thanks to the switch from standard products to extended half-life products. These novel drugs are showing beneficial effects overcoming current prophylaxis limitations by reducing the infusion frequency, maintaining a higher trough level to ensure a lower risk of bleeding, and making treatment significantly less distressing to patients by improving the quality of life. Real-life data on the efficacy of novel drugs and their impact on routine management of haemophilia A and B patients are still limited. This manuscript reports the results of a European survey conducted by the European Association for Haemophilia and Allied Disorders (EAHAD) at the beginning of 2018 on the clinical management of patients using extended half-life recombinant FIX fusion products, since at the time of the survey none of the PEGylated products were available yet. We report data on the efficacy of these novel drugs by 33 European haemophilia centres that have already switched to extended half-life fusion products, showing a reduction in the number of infusions and a satisfactory trough levels in the clinical care of haemophilia patients, with a greater impact on haemophilia B.

© 2019 John Wiley & Sons Ltd.

KEYWORDS: extended half-life products; hemophilia; infusion; treatment; trough level

PMID: 31418967 DOI: [10.1111/hae.13834](https://doi.org/10.1111/hae.13834)

lia

ndazione

Brussels,

ed half-life

uency,

y

and B

ophilia

FVIII and

ncy of

significant

ct for